{"id":"ecnoglutide-low-dosage","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL5095115","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ecnoglutide binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. This mechanism also slows gastric emptying and promotes satiety, contributing to improved blood glucose levels and potential weight reduction in patients with type 2 diabetes.","oneSentence":"Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:28.573Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05680155","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2022-12-29","conditions":"T2DM, Type 2 Diabetes Mellitus","enrollment":211},{"nctId":"NCT05680129","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-01-10","conditions":"T2DM, Type 2 Diabetes Mellitus","enrollment":623},{"nctId":"NCT05813795","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity","status":"COMPLETED","sponsor":"Hangzhou Sciwind Biosciences Co., Ltd.","startDate":"2023-04-05","conditions":"Weight Management","enrollment":664}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XW003"],"phase":"phase_3","status":"active","brandName":"Ecnoglutide Low Dosage","genericName":"Ecnoglutide Low Dosage","companyName":"Hangzhou Sciwind Biosciences Co., Ltd.","companyId":"hangzhou-sciwind-biosciences-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}